What are the typical appearance, diagnosis, and treatment of impetigo on the arm?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Impetigo on the Arm: Clinical Appearance, Diagnosis, and Treatment

Clinical Appearance

Impetigo on the arm typically presents as erythematous papules that rapidly evolve into vesicles and pustules, eventually forming characteristic thick honey-colored crusts. 1

Nonbullous Impetigo (70% of cases)

  • Begins as small red papules that quickly progress to vesicles containing cloudy fluid 1
  • Vesicles rupture within 4-6 days, leaving the pathognomonic honey-colored or golden-yellow crusts 1
  • Lesions commonly appear on exposed areas including the extremities 1
  • Regional lymphadenitis may be present, though systemic symptoms are typically absent 1

Bullous Impetigo (30% of cases)

  • Characterized by fragile, thin-roofed vesicopustules that rapidly enlarge into flaccid bullae (>5mm diameter) 1
  • Caused exclusively by toxin-producing Staphylococcus aureus strains 1
  • More likely to affect intertriginous areas but can occur on arms 2

Diagnosis

The diagnosis is primarily clinical based on the characteristic appearance of honey-colored crusts or bullae. 1

When to Obtain Cultures

  • Treatment failure after 48-72 hours of appropriate therapy 1, 3
  • Suspected methicillin-resistant S. aureus (MRSA) infection 1, 3
  • Recurrent infections 1, 3
  • Culture vesicle fluid, pus, erosions, or ulcers to establish the causative organism 1

Differential Diagnosis to Consider

  • Folliculitis (more superficial, inflammation confined to epidermis) 1
  • Impetiginized eczema (secondary infection on underlying atopic dermatitis) 1
  • Ecthyma (deeper infection with circular erythematous ulcers) 1

Treatment Algorithm

For Localized Impetigo (Few Lesions)

Topical mupirocin 2% ointment applied three times daily for 5-7 days is the first-line treatment. 1, 3

  • Topical antibiotics are superior to placebo (RR 2.24,95% CI 1.61-3.13) and equal or superior to oral antibiotics for localized disease 1
  • Alternative: Retapamulin 1% ointment applied twice daily for 5 days 3, 4
  • Mupirocin and fusidic acid show equivalent efficacy 1, 5

For Extensive Impetigo (Multiple Sites or Numerous Lesions)

Oral antibiotics should be used when impetigo involves multiple sites, is extensive, topical therapy is impractical, or topical treatment has failed. 1, 3

For Methicillin-Susceptible S. aureus (MSSA):

  • Dicloxacillin 250 mg four times daily for adults (7-10 days) 3, 4
  • Alternative: Cephalexin 250-500 mg four times daily for adults (7-10 days) 3, 4
  • Pediatric dosing: Dicloxacillin 12 mg/kg/day divided into 4 doses 3

For Suspected or Confirmed MRSA:

  • Clindamycin 300-450 mg three times daily for adults 3, 4
  • Alternative: Trimethoprim-sulfamethoxazole (TMP-SMX) 1, 4
  • Alternative: Doxycycline (avoid in children <8 years and pregnant women) 3, 4

Common Pitfalls to Avoid

  • Never use penicillin alone - it lacks adequate coverage against S. aureus and is inferior to other antibiotics 4, 5
  • Topical disinfectants are inferior to antibiotics and should not be used 1, 5
  • Tetracyclines (doxycycline, minocycline) must not be used in children under 8 years of age 1, 3

Adjunctive Measures

  • Keep lesions covered with clean, dry bandages to prevent spread 1, 3
  • Maintain good personal hygiene with regular handwashing 3
  • Debride crusts gently to improve topical antibiotic penetration 6

Monitoring and Follow-Up

  • Re-evaluate if no improvement after 48-72 hours of therapy 1, 3
  • If treatment fails, obtain cultures and adjust therapy based on susceptibility results 1, 3
  • Most cases resolve within 2-3 weeks without scarring 2

References

Guideline

Impetigo Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Impetigo: diagnosis and treatment.

American family physician, 2014

Guideline

Treatment of Non-Bullous Impetigo

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Scalp Impetigo

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Interventions for impetigo.

The Cochrane database of systematic reviews, 2012

Research

Bacterial diseases of the skin.

Journal of long-term effects of medical implants, 2005

Related Questions

What are the clinical manifestations and treatment options for impetigo?
What is the first line of treatment for a 19-month-old child suspected of having Impetigo, presenting with skin lesions on the cheeks and legs?
Does impetigo bullosa ever require inpatient treatment?
What is the diagnosis and treatment for bullous impetigo?
Can impetigo (a bacterial skin infection) present without yellow crusty discharge on the face?
What is the appropriate initial pharmacologic plan for a 21‑year‑old female with persistent anxiety despite fluoxetine 10 mg daily and newly onset ADHD symptoms?
What are the recommended doses of injectable cefotaxime (Monocef), benzyl‑penicillin G (Pan), and ondansetron (Emset) for a 5‑year‑old child weighing 17.5 kg?
Why are antinuclear antibody (ANA) and complement component 3 (C3) tests ordered in a patient with suspected systemic lupus erythematosus presenting with rash, arthritis, renal or hematologic abnormalities?
What is the recommended initial levothyroxine dose and titration protocol for a newly diagnosed healthy adult with hypothyroidism in primary care?
How should we manage a 27-year-old male with possible early syphilis (initial serology insufficient) and a current herpes outbreak, given benzathine penicillin G (Bicillin) is on back‑order, he is on doxycycline, and he requests acyclovir ointment and a prescription for the penicillin injection?
What are the indications, dosing regimen, monitoring requirements, contraindications, and alternative therapies for blinatumomab (bispecific T‑cell engager) in patients with relapsed or refractory Philadelphia chromosome‑negative B‑cell precursor acute lymphoblastic leukemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.